Researchers at Mount Sinai School of Medicine have discovered a novel component of the influenza virus that may be the key to disabling the virus's ability to replicate itself and to developing a universal anti-viral treatment. The findings were published June 1 online in Proceedings of the...
Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free injection therapy systems (NFITS), announced that the Centers for Disease Control and Prevention (CDC) and its collaborating institutions presented the latest results of its clinical trial of the Biojector® 2000...
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that Dr. Manfred Beilharz, Chair of Microbiology and Immunology, School of Biomedical, Biomolecular and Chemical Sciences, The University of Western Australia, has submitted a final report on the recently completed 200 subject...
A University of Alberta-led research team has discovered an influenza detector gene that could potentially prevent the transmission of the virus to humans. Katharine Magor, a U of A associate professor of biology, has identified the genetic detector that allows ducks to live, unharmed, as the...
A University of Alberta-led research team has discovered an influenza detector gene that could potentially prevent the transmission of the virus to humans. Katharine Magor, a U of A associate professor of biology, has identified the genetic detector that allows ducks to live, unharmed, as the...
A University of Alberta-led research team has discovered an influenza detector gene that could potentially prevent the transmission of the virus to humans. Katharine Magor, a U of A associate professor of biology, has identified the genetic detector that allows ducks to live, unharmed, as the...
Evidence for the safety and efficacy of influenza vaccines in the over 65s is poor, despite the fact that vaccination has been recommended for the prevention of influenza in older people for the past 40 years. These are the conclusions of a new Cochrane Systematic Review. Adults aged 65 and over...
Australia's Chief Medical Officer, Professor Jim Bishop, is calling on GPs to promote vaccination against the pandemic (H1N1) 2009 influenza to their patients before the flu season begins in Australia . Professor Bishop has enlisted the support of his GP Roundtable, which includes...
It is not too late for those who have not been immunized against the novel H1N1 influenza A virus or seasonal influenza to protect themselves from a potentially serious and possibly fatal illness. "Flu is very unpredictable," said Dr. Peter Wenger, an associate professor in the departments of...
The Alabama Department of Public Health is returning 5,200 doses of H1N1 influenza vaccine because of a voluntary recall from the manufacturer. The recall was issued for reasons unrelated to vaccine safety. These lots of vaccine were manufactured for infants and children 6 to 35 months of...
The U.S. Food and Drug Administration today approved Fluzone High-Dose, an inactivated influenza virus vaccine for people ages 65 years and older to prevent disease caused by influenza virus subtypes A and B. People in this age group are at highest risk for seasonal influenza complications...
A daily update on swine flu issued by the National Public Health Service for Wales. Spread and extent of the outbreak (information as at 5pm on 15 December) The NPHS influenza surveillance scheme, which records reports of diagnoses of flu from more than 300 GP practices across Wales, shows...
The U.S. Food and Drug Administration approved Agriflu for people ages 18 years and older to prevent disease caused by influenza virus subtypes A and B.
More...
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced that Dr. Eugene Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent FluCide™ animal study on November 19th at the Influenza Congress USA 2009 in Washington, DC (http://www.terrapinn.com/usaflu). These data...
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced that Dr. Eugene Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent FluCide™ animal study on November 19th at the Influenza Congress USA 2009 in Washington, DC (http://www.terrapinn.com/usaflu). These data...